一、虽然是精神病，但没关系 一部聚焦心理议题的韩剧《虽然是精神病但没关系》因部分情节尺度引发观众热议。这部剧凭借独特的 题材和深刻的社会关照，开播前便备受瞩目，被不少媒体列为年度值得关注的作品之一。 但几天前，韩国放送通信委员会透露称，EP3播出后，收到了50多条有关"剧情尺度过大"的投诉。 投诉中指出：高文英闯入男更衣室，不仅赤裸裸地紧盯文康泰的身体，更是不顾对方的拒绝，贴身抚 摸。 除此之外，台词尺度也饱受争议。在医院的大厅里，当着众人面，高文英说："对我为什么这么冷冰 冰？明明晚上那样火热？我确实欲求不满，要和我睡一次吗？" 第三集故事的主人公权起道，更是可以被直接扣上"暴露狂"的名声。 初登场便是以全裸状态突然冲到女主车前；在医院监控镜头下故意脱衣服，还说"就喜欢有人看我"；他 会因为兴奋对着夜店所有人喊出"今晚我买单"，被爸爸的保镖追赶时，脱掉衣服在路上狂奔。 最失控的一幕是，权起道冲上了父亲的竞选台，脱了衣服。 观众看这部剧，"不适感"是非常直观的反应，"这人神经病吧"会脱口而出。 是的，他们都是神经病。 一方面，双相病发的年龄范围很广，通常来说，双相在成年早期开始出现（15~19岁），但也可能在 ...

Financial Data and Key Metrics Changes - The company has seen significant growth in its integrated delivery network (IDN) sales, which were up 12 times from 2024 to 2023, indicating a strong market acceptance of its product [21] - The redesign of Medicare Part D is expected to provide a significant tailwind, with patients now having a $2,000 cap on out-of-pocket expenses, which is anticipated to drive higher fill rates and net sales [42][45] Business Line Data and Key Metrics Changes - The company’s product, Furosex, is designed to deliver 100% bioavailable furosemide, which is equivalent to the IV treatment in hospitals, allowing patients to manage their condition at home [6][14] - The approval for chronic kidney disease (CKD) indication is expected to expand the total addressable market (TAM), with approximately 700,000 patients having CKD without heart failure, and many patients suffering from both conditions [27][29] Market Data and Key Metrics Changes - The company is focusing on integrated delivery networks (IDNs) where physicians are financially aligned with hospitals, which enhances the value proposition of Furosex [19] - There is a noted difference in how various IDNs operate, with larger systems like Kaiser and the VA being more closed and structured, while smaller IDNs may require tailored protocols for best practices [25][26] Company Strategy and Development Direction - The company aims to capture the value proposition of its product by focusing on early intervention in heart failure patients to prevent hospitalizations [10][17] - The introduction of an auto-injector is expected to simplify the treatment process, reduce costs of goods sold (COGS) by 70%, and extend intellectual property protection until 2040 [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the impact of the Medicare redesign, which is expected to facilitate patient access to the drug and drive sales growth [39][46] - The expansion of the sales force is anticipated to take time to show results, but early indicators suggest positive trends in sales as more representatives engage with healthcare providers [54] Other Important Information - The company has developed internal protocols for IDNs to share best practices, which is crucial for smaller networks that may lack established guidelines [24][26] - The management highlighted the importance of addressing the needs of patients who are discharged from hospitals with residual congestion, as this presents an opportunity for Furosex to prevent readmissions [15][17] Q&A Session Summary Question: How does the company see the balance between preventing hospitalizations and reducing length of stay? - The company aims to intervene early when patients first show signs of worsening heart failure, thus preventing the need for hospitalization [10][11] Question: Are hospitals with higher readmission rates embracing Furosex? - There is a need for education among hospital staff, particularly among cardiologists who may not be fully aware of the benefits of Furosex [18] Question: How does the CKD indication expand opportunities? - The CKD indication opens up a new market segment, particularly for patients with cardiorenal disease, which is expected to drive growth [27][29] Question: What are the expected impacts of the Medicare Part D redesign? - The redesign is anticipated to lower out-of-pocket costs for patients, thereby increasing fill rates and driving sales growth [39][45] Question: How does the auto-injector fit into the company's strategy? - The auto-injector is expected to simplify the treatment process and significantly reduce costs, while also appealing to a broader patient base [49][51]